AposHealth® is an effective alternative to joint replacement surgery for end-stage knee/hip osteoarthritis. It is based on well-established biomechanical principles of reducing joint forces and muscle retraining to improve patients’ symptoms. The patented Apos® medical device provides the ability to address both critical factors of osteoarthritis and is the only one of its kind on the market.
As healthcare systems work hard to tackle the elective care backlog and reduce the health inequality because of the coronavirus (COVID-19) pandemic, patients suffering from moderate to severe knee osteoarthritis have very few effective treatment options other than surgery. For those eligible for joint replacement surgery, they face long waits, for those unsuitable for surgery, there is no effective non-invasive treatment.
AposHealth can help manage the growing and unsustainable demand for joint replacement surgery.
One of the key challenges for an SME like AposHealth is to ensure the foundation for adoption across the NHS is fully established. The path for uptake of medical devices is varied and, in many cases, unclear within the NHS, understanding funding mechanisms, engaging with key stakeholders and decision makers has been a challenge. AposHealth are currently undertaking a formal evaluation with NICE.
To try and encourage greater adoption and spread of the device, Apos applied to the AHSN Network’s Health Tech Connect service (now replaced by the NHS Innovation Service), which steered them towards the process of formal evaluation by NICE (Medical Technologies Guidance). This will help build credibility if selected as a NICE approved medical device. KSS AHSN have supported the company to build evidence; apply to the NHS Supply Chain procurement system; and facilitate introductions to stakeholders across the region.